Quest Diagnostics Incorporated (NYSE: DGX) — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request refers to 2023 Q4, this filing reports full-year results; the supplied text does not provide a clear standalone fourth-quarter financial summary.
Business context
Quest provides clinical laboratory testing and related diagnostic information services, primarily in the United States. Diagnostic Information Services (DIS) generated 97% of 2023 revenue; Diagnostic Solutions includes risk-assessment and healthcare IT businesses. The company processed approximately 206 million test requisitions in 2023.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net revenues | $9.252 billion | $9.883 billion | Down 6.4% |
| Operating income | $1.262 billion | $1.428 billion | Down 11.6% |
| Operating margin | 13.6% | 14.5% | Down 0.9 percentage points |
| Net income attributable to Quest | $854 million | $946 million | Down 9.7% |
| Diluted EPS | $7.49 | $7.97 | Down 6.0% |
| Cash from operations | $1.272 billion | $1.718 billion | Down $446 million |
| Capital expenditures | $408 million | $404 million | Up $4 million |
- Revenue drivers: DIS revenue fell 6.6%, mainly because COVID-19 testing declined. Base-business revenue, including recent acquisitions, grew 7.3%; base-business volume rose 6.5%. Total DIS requisition volume declined 0.6%, while revenue per requisition fell 5.9%, primarily reflecting less COVID-19 molecular testing. Diagnostic Solutions revenue increased 0.7%.
- Cash and liquidity: Cash and cash equivalents were $686 million at year-end, versus $315 million in 2022. The company reported $1.2 billion of available borrowing capacity and no outstanding borrowings under its revolving or secured receivables facilities at year-end. Days sales outstanding increased to 50 from 47.
- Debt: Long-term debt totaled $4.713 billion, including $303 million classified as current; the filing separately describes approximately $4.7 billion of debt outstanding. Quest issued $750 million of 6.40% senior notes due 2033. The next stated senior-note maturities include $301 million due in 2024 and $606 million due in 2025.
- Capital returns: Quest repurchased 2.0 million shares for $276 million in 2023, compared with 10.1 million shares for $1.4 billion in 2022. It paid quarterly dividends of $0.71 per share in 2023 and announced an increase to $0.75 per quarter, effective with the April 2024 payment.
Material changes and unusual items
- Revenue contraction largely reflected the continuing reduction in COVID-19 testing revenue: $223 million in 2023 versus $1.454 billion in 2022. Base-business revenue increased to $9.029 billion from $8.429 billion.
- Cost of services declined 3.9% and selling, general and administrative expense declined 12.4%; nevertheless, operating margin narrowed as revenue fell faster than total operating costs.
- Operating cash flow decreased, which management attributed mainly to lower operating income and year-over-year timing and collection of COVID-19 revenue. Investing cash outflow increased to $1.061 billion, principally because acquisition spending rose.
- 2023 acquisitions included select NewYork-Presbyterian laboratory assets for $275 million and Haystack Oncology for $392 million net of acquired cash, including estimated contingent consideration. Aggregate 2023 acquisition purchase price was $699 million net of cash acquired. Haystack’s seller may receive additional payments based on revenue benchmarks and CMS reimbursement coverage.
- Reported 2023 diluted EPS was reduced by a net $1.22 from specified items, including $108 million of intangible amortization, $44 million of other charges (including a $29 million asset impairment), $43 million of restructuring and integration charges, and $3 million of equity-method investment losses; $11 million of excess stock-compensation tax benefits partly offset these items.
Outlook, risks and contingencies
- The filing gives no consolidated revenue or earnings guidance in the supplied text. Management estimated approximately $420 million of 2024 capital expenditures and said its Invigorate program aims for 3% annual cost savings and productivity improvements to help offset inflation and reimbursement pressure. The company also targets growing revenue by 1–2% annually through acquisitions as a strategic objective, not a stated financial forecast.
- Management expects diagnostic services to benefit over the long term from healthcare demand and sees opportunities in advanced testing, hospital partnerships, consumer access and efficiency. It also identifies pricing, reimbursement, utilization and competitive pressures as significant countervailing risks.
- PAMA’s next laboratory-market data collection and reporting were delayed until January 1, 2025; reimbursement reductions for 2025–2027 are capped at 15% annually under the law. Potential changes to FDA oversight of laboratory-developed tests remain an industry uncertainty.
- Other key risks include payer denials and patient concessions, labor and supply-cost inflation, competition and hospital internalization of testing, technology and AI execution, cybersecurity and privacy, and acquisition integration. The company reported no cybersecurity incident in 2023 with a material impact on operations or financial results.
- Legal matters include data-security class actions, a 401(k) fiduciary lawsuit, privacy-related litigation and government inquiries. Management said material legal losses were not believed probable at December 31, 2023, but outcomes could affect results or cash flows. Legal reserves were $6 million; general and professional liability reserves were $173 million. The filing also discloses contingent predecessor-lease obligations that could total several hundred million dollars, but management considers performance remote and recorded no liability.
Important facts for investors to verify
- Review the audited statements and notes for the full debt schedule, covenant terms, cash-flow details and any subsequent repayment or refinancing of the 2024 notes.
- Track the pace of COVID-19 revenue normalization against base-business requisition volume, revenue per requisition and acquired-business contributions.
- Assess patient concessions, payer denials and receivable collection trends, including the increase in DSO and the estimates underlying contractual allowances.
- Monitor the timing and financial impact of PAMA changes and any final FDA rules or legislation affecting laboratory-developed tests.
- Evaluate Haystack’s commercialization, reimbursement progress, contingent-payment exposure and integration, alongside the returns from other acquisitions and Invigorate savings.
- Follow the status and potential exposure of disclosed litigation and investigations, including the pending ReproSource settlement approval and the other unresolved matters.